Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial

被引：0
|
作者：
Freedman, M. [1 ]
Wolinsky, J. [2 ]
Comi, G. [3 ]
Kappos, L. [4 ]
Olsson, T. [5 ]
Miller, A. [6 ]
Benamor, M. [7 ]
Dukovic, D. [8 ]
Liang, J. [8 ]
Truffinet, P. [7 ]
O'Connor, P. [9 ]
机构：
[1] Ottawa Hosp, Ottawa, ON, Canada
[2] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Basel, Basel, Switzerland
[5] Karolinska Inst, Stockholm, Sweden
[6] Ichan Sch Med Mt Sinai, New York, NY USA
[7] Sanofi, Chilly Mazarin, France
[8] Sanofi, Bridgewater, MA USA
[9] Univ Toronto, Toronto, ON, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：225 / 225
页数：1
相关论文
共 50 条
  • [31] Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study
    O'Connor, Paul
    Comi, Giancarlo
    Freedman, Mark S.
    Miller, Aaron E.
    Kappos, Ludwig
    Bouchard, Jean-Pierre
    Lebrun-Frenay, Christine
    Mares, Jan
    Benamor, Myriam
    Thangavelu, Karthinathan
    Liang, Jinjun
    Truffinet, Philippe
    Lawson, Victoria J.
    Wolinsky, Jerry S.
    [J]. NEUROLOGY, 2016, 86 (10) : 920 - 930
  • [32] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Krakovich, A.
    Sheffield, J. K.
    Cheng, C. -Y.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 359 - 360
  • [33] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [34] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: interim analysis of the DAYBREAK open-label extension study
    Selmaj, K. W.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, K.
    Hoogerheyde, J.
    Afsari, S.
    Sheffield, J. K.
    Shi, F.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 617 - 618
  • [35] Efficacy of oral teriflunomide in multiple sclerosis with relapses: cognitive outcomes from a phase III trial (TEMSO)
    Miller, A.
    O'Connor, P.
    Wolinsky, J.
    Confavreux, C.
    Comi, G.
    Kappos, L.
    Olsson, T.
    Truffinet, P.
    Wang, L.
    Freedman, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S182 - S182
  • [36] Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies
    Sprenger, Till
    Kappos, Ludwig
    Sormani, Maria Pia
    Miller, Aaron E.
    Poole, Elizabeth M.
    Cavalier, Steven
    Wuerfel, Jens
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (11) : 1719 - 1728
  • [37] Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
    Confavreux, Christian
    Li, David K.
    Freedman, Mark S.
    Truffinet, Philippe
    Benzerdjeb, Hadj
    Wang, Dazhe
    Bar-Or, Amit
    Traboulsee, Anthony L.
    Reiman, Lucy E.
    O'Connor, Paul W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (09) : 1278 - 1289
  • [38] Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
    Sormani, Maria Pia
    Truffinet, Philippe
    Thangavelu, Karthinathan
    Rufi, Pascal
    Simonson, Catherine
    De Stefano, Nicola
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2017, 4 (05):
  • [39] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
    Cree, Bruce A. C.
    Selmaj, Krzysztof W.
    Steinman, Lawrence
    Comi, Giancarlo
    Bar-Or, Amit
    Arnold, Douglas L.
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva K.
    Sheffield, James K.
    Minton, Neil
    Cheng, Chun-Yen
    Silva, Diego
    Kappos, Ludwig
    Cohen, Jeffrey A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1944 - 1962
  • [40] Effect of Teriflunomide on Relapses with Sequelae and Relapse Leading to Hospitalization in a Population with Relapsing Forms of Multiple Sclerosis: Results from the TEMSO Study
    Miller, Aaron
    Lublin, Fred
    O'Connor, Paul
    Wolinsky, Jerry
    Comi, Giancarlo
    Kappos, Ludwig
    Freedman, Mark
    Olsson, Tomas
    Dive-Pouletty, Catherine
    Bego-Le-Bagousse, Gaelle
    Confavreux, Christian
    [J]. NEUROLOGY, 2012, 78
12345